Skip to main content

Vyvgart Hytrulo

Pronunciation: VIV-gart hy-TRUE-lo
Generic name: efgartigimod alfa and hyaluronidase-qvfc
Dosage form: single-dose prefilled syringe for subcutaneous injection (efgartigimod alfa 1000 mg/hyaluronidase 10,000 units), single-dose vial for subcutaneous injection (efgartigimod alfa 1008 mg/ hyaluronidase 11,200 units)
Drug class: Immune globulins

Medically reviewed by Carmen Pope, BPharm. Last updated on Jul 9, 2025.

What is Vyvgart Hytrulo?

Vyvgart Hytrulo is used to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, or adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It is given subcutaneously (under the skin) once a week and can be self-administered or administered by a caregiver or healthcare provider. 

Vyvgart Hytrulo contains a combination of efgartigimod alfa (the active ingredient) and hyaluronidase (an enzyme) and can be self-administered or administered by a caregiver or healthcare provider. Efgartigimod alfa is a fragment of an IgG antibody that works by attaching to and blocking a protein called neonatal Fc receptor (FcRn), which binds circulating IgG antibodies. This keeps the FcRN receptors occupied, so more IgG antibodies remain unattached and are removed from the body. This helps treat CIDP and gMG, conditions where harmful antibodies damage nerves and muscles. The hyaluronidase component allows Vyvgart Hytrulo to be given subcutaneously. Hyaluronidase is an enzyme that temporarily increases the permeability of subcutaneous tissue by depolymerizing a critical component of the skin's structure called hyaluronan, allowing larger injection quantities to be given subcutaneously. The integrity of the subcutaneous tissue is restored within 24 to 48 hours.

Vyvgart Hytrulo first gained FDA approval on June 20, 2023, for gMG, and approval was extended on June 21, 2024, to cover CIDP. For information on the IV formulation of efgartigimod alfa, see Vyvgart.

Side effects

The most common side effects of Vyvgart Hytrulo are:

Serious side effects and warnings

Vyvgart Hytrulo can cause the following serious side effects.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before receiving this medicine

Do not receive Vyvgart Hytrulo if you are allergic to efgartigimod alfa, hyaluronidase, Vyvgart, Vyvgart Hytrulo, or any of the inactive ingredients in the preparation. 

To make sure Vyvgart Hytrulo is safe for you, tell your doctor if you:

Pregnancy

It is not known whether Vyvgart Hytrulo will harm your unborn baby.

Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use Vyvgart Hytrulo during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to https://www.Vyvgartpregnancy.com

Breastfeeding

It is not known if Vyvgart Hytrulo passes into your breast milk.  

How do I give Vyvgart Hytrulo?

Administer Vyvgart Hytrulo exactly as your healthcare provider tells you to.

Vyvgart Hytrulo comes in a single-dose prefilled syringe and single-dose vial.

Vyvgart Hytrulo is given as a slow and steady injection.

Dosing information

Dose of Vyvgart Hytrulo for gMG (adults)

Subsequent treatment cycles may be administered based on clinical evaluation.

Dose of Vyvgart Hytrulo for CIDP (adults)

What happens if I miss a dose?

If you miss a dose, you may give the injection for up to 3 days after the missed dose. After that, continue with the normal time between doses (dosing schedule).

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while receiving Vyvgart Hytrulo?

You should avoid receiving live vaccines, such as the chickenpox, measles, or mumps vaccines, while being treated with this medicine.

What other drugs will affect Vyvgart Hytrulo?

Vyvgart Hytrulo may interact with other prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use, and when you start, stop, or change a dose of any medicine.

Care should be taken when using Vyvgart Hytrulo with other medications that bind to the human neonatal Fc receptor (FcRn) (such as immunoglobulin products, monoclonal antibodies, or antibody derivatives containing the human Fc domain of the IgG subclass) because it may reduce the effectiveness of these medications.

Does Vyvgart Hytrulo interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Storage

Refrigerator

Store Vyvgart Hytrulo in the refrigerator between 36°F to 46°F (2°C to 8°C).

Only warm Vyvgart Hytrulo just before use by letting it sit on a flat surface for at least 30 minutes for the prefilled syringe and 15 minutes for the vial. Do not warm Vyvgart Hytrulo any other way (eg, with an external heat source).

Remove from the refrigerator only the dose you are preparing to inject. Future doses should remain refrigerated until ready to use.

Room temperature

If needed, Vyvgart Hytrulo may be stored at room temperature. Record the date you removed Vyvgart Hytrulo from the refrigerator.

Keep  Vyvgart Hytrulo and all medicines out of the reach of children.

Ingredients

Active ingredients: efgartigimod alfa and hyaluronidase (human recombinant)

Inactive ingredients:

Vyvgart Hytrulo is available as:

Preservative-free.

Manufacturer

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is manufactured by:

It is distributed by argenx US, Inc. 33 Arch Street, Boston, MA 02110.

Vyvgart hytrulo Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for Vyvgart Hytrulo.

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) - Argenx BV
Formulation type Strength
Pre-Filled Syringe 1,000 mg/5 mL;10,000 units/5 mL (200 mg/2,000 units/mL)
Single-Dose Vial 1,008 mg/5.6 mL; 11,200 units/5.6 mL (180 mg/2,000 units/mL)

Popular FAQ

What is the difference between Vyvgart and Vyvgart Hytrulo?

Vyvgart and Vyvgart Hytrulo both contain the same active ingredient, efgartigimod, but there are differences in their uses and the way they are given, for example Vyvgart Hytrulo can be self-administered using a prefilled syringe for subcutaneous (SC) injection, whereas Vyvgart must be given by intravenous (IV) infusion by a healthcare provider.

Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.